Agathe Margulies, Nassim Sahki, Fabien Rech, Guillaume Vogin, Marie Blonski, Didier Peiffert, Luc Taillandier, Grégory Lesanne, Nicolas Demogeot
{"title":"成人胶质母细胞瘤分次立体定向再照射后的复发模式。","authors":"Agathe Margulies, Nassim Sahki, Fabien Rech, Guillaume Vogin, Marie Blonski, Didier Peiffert, Luc Taillandier, Grégory Lesanne, Nicolas Demogeot","doi":"10.1186/s13014-025-02611-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Glioblastomas all eventually relapse after initial treatment, and an option to treat these recurrences is fractionated stereotactic reirradiation (fSRT). The location of recurrences following reirradiation has not been studied for fSRT delivered by a dedicated stereotactic device. We aimed to analyze these locations to better elucidate safety margins, dose and fractionation regimens.</p><p><strong>Methods: </strong>We retrospectively analyzed the data of patients with glioblastoma recurrence that had been reirradiated by fSRT in October 2010-December 2020, in 25 Gy in 5 fractions delivered by a CyberKnife<sup>®</sup> at Institut de Cancérologie de Lorraine. We matched the images of the post-fSRT relapse with the stereotactic radiation treatment planning scan to determine the relapse location.</p><p><strong>Results: </strong>The location of recurrences after fSRT was \"out-field\" in 43.5%, \"marginal\" in 40.3%, and \"in-field\" in 16.1% of patients (N = 62). A GTV-PTV margin of 1 mm (versus 2-3 mm, HR = 0.38 [0.15-0.95], p = 0.037) and a PTV volume of ≥ 36 cc (HR = 5.18 [1.06-25.3], p = 0.042) were significantly associated with the \"marginal\" recurrences. Being ≥ 60 years old at initial treatment (HR = 3.06 [1.17-8.01], p = 0.023) and having one or more previous recurrences (HR = 5.29 [1.70-16.5], p = 0.004) were significantly associated with \"out-field\" recurrences. The median PFS from fSRT was 3.4 months, and OS from diagnosis and from fSRT were 25.7 and 10.8 months respectively.</p><p><strong>Conclusion: </strong>Reirradiation of glioblastoma recurrence by fSRT with 25 Gy in 5 fractions provides good local control.</p>","PeriodicalId":49639,"journal":{"name":"Radiation Oncology","volume":"20 1","pages":"28"},"PeriodicalIF":3.3000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871646/pdf/","citationCount":"0","resultStr":"{\"title\":\"Pattern of recurrence after fractionated stereotactic reirradiation in adult glioblastoma.\",\"authors\":\"Agathe Margulies, Nassim Sahki, Fabien Rech, Guillaume Vogin, Marie Blonski, Didier Peiffert, Luc Taillandier, Grégory Lesanne, Nicolas Demogeot\",\"doi\":\"10.1186/s13014-025-02611-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Glioblastomas all eventually relapse after initial treatment, and an option to treat these recurrences is fractionated stereotactic reirradiation (fSRT). The location of recurrences following reirradiation has not been studied for fSRT delivered by a dedicated stereotactic device. We aimed to analyze these locations to better elucidate safety margins, dose and fractionation regimens.</p><p><strong>Methods: </strong>We retrospectively analyzed the data of patients with glioblastoma recurrence that had been reirradiated by fSRT in October 2010-December 2020, in 25 Gy in 5 fractions delivered by a CyberKnife<sup>®</sup> at Institut de Cancérologie de Lorraine. We matched the images of the post-fSRT relapse with the stereotactic radiation treatment planning scan to determine the relapse location.</p><p><strong>Results: </strong>The location of recurrences after fSRT was \\\"out-field\\\" in 43.5%, \\\"marginal\\\" in 40.3%, and \\\"in-field\\\" in 16.1% of patients (N = 62). A GTV-PTV margin of 1 mm (versus 2-3 mm, HR = 0.38 [0.15-0.95], p = 0.037) and a PTV volume of ≥ 36 cc (HR = 5.18 [1.06-25.3], p = 0.042) were significantly associated with the \\\"marginal\\\" recurrences. Being ≥ 60 years old at initial treatment (HR = 3.06 [1.17-8.01], p = 0.023) and having one or more previous recurrences (HR = 5.29 [1.70-16.5], p = 0.004) were significantly associated with \\\"out-field\\\" recurrences. The median PFS from fSRT was 3.4 months, and OS from diagnosis and from fSRT were 25.7 and 10.8 months respectively.</p><p><strong>Conclusion: </strong>Reirradiation of glioblastoma recurrence by fSRT with 25 Gy in 5 fractions provides good local control.</p>\",\"PeriodicalId\":49639,\"journal\":{\"name\":\"Radiation Oncology\",\"volume\":\"20 1\",\"pages\":\"28\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-02-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871646/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Radiation Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13014-025-02611-0\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13014-025-02611-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Pattern of recurrence after fractionated stereotactic reirradiation in adult glioblastoma.
Background: Glioblastomas all eventually relapse after initial treatment, and an option to treat these recurrences is fractionated stereotactic reirradiation (fSRT). The location of recurrences following reirradiation has not been studied for fSRT delivered by a dedicated stereotactic device. We aimed to analyze these locations to better elucidate safety margins, dose and fractionation regimens.
Methods: We retrospectively analyzed the data of patients with glioblastoma recurrence that had been reirradiated by fSRT in October 2010-December 2020, in 25 Gy in 5 fractions delivered by a CyberKnife® at Institut de Cancérologie de Lorraine. We matched the images of the post-fSRT relapse with the stereotactic radiation treatment planning scan to determine the relapse location.
Results: The location of recurrences after fSRT was "out-field" in 43.5%, "marginal" in 40.3%, and "in-field" in 16.1% of patients (N = 62). A GTV-PTV margin of 1 mm (versus 2-3 mm, HR = 0.38 [0.15-0.95], p = 0.037) and a PTV volume of ≥ 36 cc (HR = 5.18 [1.06-25.3], p = 0.042) were significantly associated with the "marginal" recurrences. Being ≥ 60 years old at initial treatment (HR = 3.06 [1.17-8.01], p = 0.023) and having one or more previous recurrences (HR = 5.29 [1.70-16.5], p = 0.004) were significantly associated with "out-field" recurrences. The median PFS from fSRT was 3.4 months, and OS from diagnosis and from fSRT were 25.7 and 10.8 months respectively.
Conclusion: Reirradiation of glioblastoma recurrence by fSRT with 25 Gy in 5 fractions provides good local control.
Radiation OncologyONCOLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
CiteScore
6.50
自引率
2.80%
发文量
181
审稿时长
3-6 weeks
期刊介绍:
Radiation Oncology encompasses all aspects of research that impacts on the treatment of cancer using radiation. It publishes findings in molecular and cellular radiation biology, radiation physics, radiation technology, and clinical oncology.